Benefit Corporation: a path to affordable gene therapies?

With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    High, K. A. & Roncarolo, M. G. N. Engl. J. Med. 381, 455–464 (2019).

    Article  Google Scholar 

  2. 2.

    Marsden G., Towse, A., Pearson, S. D., Dreitlin, B. & Henshall, C. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value (2017).

  3. 3.

    Bach, P. B. ‘Anchoring’ was at work in setting the price of Novartis’ new gene therapy. STAT (2019).

  4. 4.

    Brody, B. The Hastings Center Report 26, 5–11 (1996).

    CAS  Article  Google Scholar 

  5. 5.

    World Health Organization. Improving the Transparency of Markets for Medicines, Vaccines, and Other Health Products [footnote]. (2019).

  6. 6.

    Cummings, B. Columbia Law Rev. 112, 578–627 (2012).

    Google Scholar 

  7. 7.

    Business Roundtable. Our Commitment. (2019).

Download references

Author information



Corresponding authors

Correspondence to Alain Fischer or Michel Goldman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fischer, A., Dewatripont, M. & Goldman, M. Benefit Corporation: a path to affordable gene therapies?. Nat Med 25, 1813–1814 (2019).

Download citation

Further reading